

11-17-06


PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

IFW

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission		Attorney Docket Number	TJU0016-100 (WAL_SCO.008/CGG)
--	--	------------------------	-------------------------------

ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): PTO SB/08a and b (11pp.); 122 references cited; 74 references submitted; return card.
Remarks EXPRESS MAIL LABEL NO: EV 882773845 US DATE OF DEPOSIT:		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm	Cozen O'Connor		
Signature			
Printed Name	Marc DeLuca		
Date	Nov 16 2006	Reg. No.	33,229

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature			
Typed or printed name			
Date			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



DOCKET NO: TJU0016-100(WAL_SCO.008/CGG)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: **Scott Waldmann et al.**

Serial No.: **10/775,481**

Group Art Unit: **1642**

Filing Date: **February 10, 2004**

Examiner: **Catherine Joyce**

For: **Use of GCC Ligands**

EXPRESS MAIL LABEL NO: EV 882773845 US

DATE OF DEPOSIT: Nov 16 2006

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Forms SB/08A and SB/08B, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made.

This Supplemental Information Disclosure Statement is being filed:

- within three months of the filing date of the patent application.
- within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.

- before the mailing date of a first Office Action on the merits.
- before the mailing date of a first Office Action on the merits after the filing of a Request for Continued Examination under § 1.114.
- after the mailing date of a first Office Action on the merits or after the filing of a Request for Continued Examination under § 1.114, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
 - the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);
or
 - the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
 - No fee is owed by the applicant(s).
- In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with the first or second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- after the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before, or simultaneously with, the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), and the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p).
- Copies of references listed on the attached PTO Forms SB/08A and PTO Forms SB/08B are enclosed.

EXCEPT THAT:

- In view of the voluminous nature of references BW, CC, CN, CW, DA, DH, DO, DU, DW, and EE and the likelihood that these reference are available to the Examiner, copies are not enclosed herewith.
- In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.
- If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Statement under 37 C.F.R. § 1.97(e)

- The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

Statement under 37 C.F.R. § 1.704(d)

- The undersigned attorney hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and the communication was not received by any individual designated in §1.56(c) more than 30 days prior to the filing of the Information Disclosure Statement.


Fees

- No Fee is owed by the applicant(s).
- The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.
- The Petition Fee of \$130.00 under 37 C.F.R. § 1.17(i)(1) is enclosed herewith.

Method of Payment of Fees

- Attached is a check in the amount of \$_____ This form is submitted in duplicate.
- Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.
- Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.
- No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,

Mark DeLuca
Registration No. 33,229

Dated: Nov 16 2006

COZEN O'CONNOR, P.C.
1900 Market Street, 5th Floor
Philadelphia, PA 19103-3508
(215) 665-2000 – Telephone
(215) 665-2013 - Facsimile



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Approved for use through 07/01/2008. GPO 0007-000.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

~~Substitute for form 1449A/PTC~~

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 11

Complete If Known	
Application Number	10/775481
Filing Date	February 10, 2004
First Named Inventor	Scott Waldman
Art Unit	1642
Examiner Name	Catherine Joyce
Attorney Docket Number	TJU0016-100 (WAL SCO.008/CGG)

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	AA	US-5,518,888	05-21-1996	Scott A Waldmann et al.	
	AB	US-5,879,656	03-09-1999	Scott A Waldmann et al.	
	AC	US-6,060,037	05-09-2000	Scott A Waldmann et al.	
	AD	US-6,268,159	07-31-2001	Scott A Waldmann et al.	
	AE	US-5,601,990	02-11-1997	Scott A Waldmann et al.	
	AF	US-5,731,159	03-24-1998	Scott A Waldmann et al.	
	AG	US-5,928,873	07-27-1999	Scott A Waldmann et al.	
	AH	US-5,962,220	10-05-1999	Scott A Waldmann et al.	
	AI	US-6,087,109	07-11-2000	Scott A Waldmann et al.	
	AJ	US-6,767,704	07-27-2004	Scott A Waldmann et al.	
	AK	US-5,530,101	06-25-1996	Cary L. Queen et al.	
	AL	US-5,585,089	01-17-1996	Cary L. Queen et al.	
	AM	US-5,225,539	07-06-1993	Gregory P. Winter et al.	
	AN	US-5,270,170	12-14-1993	Schatz et al.	
	AO	US-5,338,665	08-16-0994	Schatz et al.	
	AP	US-5,395,750	03-07-1995	Dillon et al.	
	AQ	US-5,223,409	6-29-1993	Ladner et al	

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST-3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST-16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<i>Application Number</i>	10/775481
		<i>Filing Date</i>	February 10, 2004
		<i>First Named Inventor</i>	Scott Waldman
		<i>Art Unit</i>	1642
		<i>Examiner Name</i>	Catherine Joyce
<i>(Use as many sheets as necessary)</i>		<i>Attorney Docket Number</i>	
Sheet	2	of	11
TJU0016-100 (WAL_SCO.008/CGG)			

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	AU	US-5,366,862	11-22-1994	Venton et al.	
	AV	US-5,340,474	08-23-1994	Kauvar et al	
	AW	US-5,133,866	07-28-1992	Lawrence M. Kauvar et al.	
	AX	US-4,963,263	10-16-1990	Lawrence M. Kauvar et al.	
	AY	US-5,217,869	06-08-1993	Lawrence M. Kauvar et al.	
	AZ	US-5,405,783	04-11-1995	Pirrung et al.	
	BA	US-5,143,854	09-01-1992	Pirrung et al.	
	BB	US-5,384,261	01-24-1995	Winkler et al.	
	BC	US-5,221,736	06-22-1993	Coolidge et al.	
	BD	US-5,412,087	05-02-1995	McGall et al.	
	BE	US-5,324,483	06-28-1994	Cody et al.	
	BF	US-5,252,743	10-12-1993	Barret et al.	
	BG	US-5,424,186	06-13-1995	Foder et al.	
	BH	US-5,420,328	05-30-1995	Campbell et al.	
	BI	US-5,288,514	02-22-1994	Elliman et al.	
	BJ	US-4,601,896	07-22-1986	Mark Nugent et al.	
	BK	US-4,729,893	03-08-1988	Robert L. Letcher et al.	

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

⁴EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ⁵Applicant's unique citation designation number (optional). ⁶See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁷Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁸For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁹Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ¹⁰Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<i>Application Number</i>	10/775481
		<i>Filing Date</i>	February 10, 2004
		<i>First Named Inventor</i>	Scott Waldman
		<i>Art Unit</i>	1642
		<i>Examiner Name</i>	Catherine Joyce
<i>(Use as many sheets as necessary)</i>		<i>Attorney Docket Number</i>	TJU0016-100 (WAL_SCO.008/CGG)
Sheet	3	of	11

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

⁴EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ⁵Applicant's unique citation designation number (optional). ⁶See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁷For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁸Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁹Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			<i>Application Number</i>	10/775481
(Use as many sheets as necessary)			<i>Filing Date</i>	February 10, 2004
			<i>First Named Inventor</i>	Scott Waldman
			<i>Art Unit</i>	1642
			<i>Examiner Name</i>	Catherine Joyce
Sheet	4	of	11	<i>Attorney Docket Number</i>
TJU0016-100 (WAL_SCO.008/CGG)				

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	BP	Ames, J. B. et al., "Three-dimensional structure of guanylyl cyclase activating protein-2, a calcium-sensitive modulator of photoreceptor guanylyl cyclases," <i>J. Biol. Chem.</i> , (1999), 274, 19329-19337.		
	BQ	Andric et al. "Dependence of soluble guanylyl cyclase activity on calcium signaling in pituitary cells," <i>J. Biol. Chem.</i> (2001), 276, 844-849		
	BR	Berridge, M. J. et al., "Calcium—a life and death signal," <i>Nature</i> (1998), 395, 645-648.		
	BS	Bhattacharya, J. et al., "Rise of intracellular free calcium levels with activation of inositol triphosphate in a human colonic carcinoma cell line (COLO 205) by heat-stable enterotoxin of <i>Escherichia coli</i> ," <i>Biochim. Biophys. Acta</i> (1998), 1403, 14		
	BT	Biel et al., "Cyclic nucleotide-gated channels--mediators of NO:cGMP-regulated processes," <i>Naunyn Schmiedeberg's Arch. Pharmacol.</i> (1998), 358, 140-144		
	BU	Birkenkamp-Demtroder, K. et al., "Gene expression in colorectal cancer," <i>Cancer Res.</i> (2002), 62, 4352-4363		
	BV	Blanchard R.K. et al., "Upregulation of rat intestinal uroguanylin mRNA by dietary zinc restriction," <i>Am. J. Physiol.</i> (1997) 272 (5Pt 1) G972-978		
	BW	Bodanszky et al, <i>Peptide Synthesis</i> , (1976) John Wiley & Sons, 2d Ed.		
	BX	Brenner et al., "Encoded combinatorial chemistry," <i>Proc. Natl. Acad. Sci. USA</i> (June 1992), 89:5381-5383.		
	BY	Briskey, E. N. et al., "Colorectal cancer: update on recent advances and their impact on screening protocols," <i>J. Natl. Med. Assoc.</i> (2000), 92(5), 222-230.		
	BZ	Buset, M. et al., "Inhibition of human colonic epithelial cell proliferation in vivo and in vitro by calcium," <i>Cancer Res.</i> (1986), 46, 5426-5430		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO			Complete if Known	
			<i>Application Number</i>	10/775481
			<i>Filing Date</i>	February 10, 2004
			<i>First Named Inventor</i>	Scott Waldman
			<i>Art Unit</i>	1642
			<i>Examiner Name</i>	Catherine Joyce
Sheet	5	of	11	<i>Attorney Docket Number</i>
TJU0016-100 (WAL_SCO.008/CGG)				

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	CA	Butt, E., "(Rp)-8-pCPT-cGMPS, a novel cGMP-dependent protein kinase inhibitor," <i>Eur. J. Pharmacol.</i> (1994), 269(2), 265-268.		T ²
	CB	Carrithers et al., "Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues," <i>Proc Natl Acad Sci USA</i> (1996) 93(25):14827-32.		
	CC	Centers for Disease Control and Prevention. (2001) in <i>Health Information for International Travel 1999–2000</i> (Department of Health and Human Services, Atlanta).		
	CD	Chan et al., "Amino acid sequence of heat-stable enterotoxin produced by <i>Escherichia coli</i> pathogenic for man," <i>J. Biol. Chem.</i> (1981), 256(15):7744-6.		
	CE	Chao, A. C. et al., "Activation of intestinal CFTR Cl- channel by heat-stable enterotoxin and guanylin via cAMP-dependent protein kinase," <i>EMBO J.</i> (1994) 1;13(5):1065-72.		
	CF	Cohen et al., " Guanylin mRNA expression in human intestine and colorectal adenocarcinoma," <i>Lab. Invest.</i> (1998), 78(1), 101-108.		
	CG	Cull M.G. et al., "Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor," <i>Proc. Natl. Acad. Sci. USA</i> (March 1992), 89:1865-1869.		
	CH	Currie, M.G. et al., "Guanylin: an endogenous activator of intestinal guanylate cyclase," <i>Proc. natl. Acad. Sci. USA</i> (1992) 89:947-951.		
	CI	Devor, D. C. et al., "Modulation of K+ channels by arachidonic acid in T84 cells. I. Inhibition of the Ca(2+)-dependent K+ channel," <i>Am. J. Physiol.</i> (1998), 274, C138-C148.		
	CJ	Dostmann, W. R. et al., "(RP)-cAMPS inhibits the cAMP-dependent protein kinase by blocking the cAMP-induced conformational transition," <i>FEBS Lett.</i> (1995), 375(3), 231-234.		
	CK	Dayhoff, M.O. et al., "A model of evolutionary change in proteins" in <i>Atlas of Protein Sequence and Structure</i> , Nat. Biomed. Res. Foundation, Washington D.C. (1978), Vol. 5, supp. 3 , chapter 22, 345-352.		

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			<i>Application Number</i>	10/775481
(Use as many sheets as necessary)			<i>Filing Date</i>	February 10, 2004
			<i>First Named Inventor</i>	Scott Waldman
			<i>Art Unit</i>	1642
			<i>Examiner Name</i>	Catherine Joyce
Sheet	6	of	11	<i>Attorney Docket Number</i>
TJU0016-100 (WAL_SCO.008/CGG)				

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	CL	Dzeja, C. et al., "Ca ²⁺ permeation in cyclic nucleotide-gated channels," <i>EMBO J.</i> 1999 Jan 4;18(1):131-44. 18, 131144.		
	CM	Fodor, S. P. A. et al., "Light-directed, spatially addressable parallel chemical synthesis," <i>Science</i> Vol 251, Issue 4995, 767-773 (Feb. 15, 1991).		
	CN	Ferlay, J., (2001) in <i>GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide</i> , Version 1.0 (International Agency for Research on Cancer, Lyon).		
	CO	Fischer, T. A et al. "Activation of cGMP-dependent protein kinase Ibeta inhibits interleukin 2 release and proliferation of T cell receptor-stimulated human peripheral T cells," 20 U., Sopper, S., & Lohmann, S. M. (2001). <i>J. Biol. Chem.</i> 276, 5967-5974		
	CP	Forte L. R., "Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology," <i>Regul. Pept.</i> (1999) May 31;81(1-3):25-39.		
	CQ	Fukumoto, S. et al., "Distinct role of cAMP and cGMP in the cell cycle control of vascular smooth muscle cells: cGMP delays cell cycle transition through suppression of cyclin D1 and cyclin-dependent kinase 4 activation," <i>Circ. Res.</i> (1999) 85(11), 985-991.		
	CR	Gadbois, D. M. et al. "Multiple kinase arrest points in the G1 phase of nontransformed mammalian cells are absent in transformed cells," <i>Proc. Natl. Acad. Sci. USA</i> (1992), 89(18), 8626-8630		
	CS	Genarro, Alfonso, ed. <i>Remington's Pharmaceutical Sciences</i> , 18 th Edition, 1990, Mack Publishing Co., Easton PA.		
	CT	Giannella, R. A. et al., "Escherichia coli heat-stable enterotoxins, guanylins, and their receptors: what are they and what do they do?" <i>J. Lab. Clin. Med.</i> (1995), 125(2), 173-181.		
	CU	Guarino, A. et al., "Small and large intestinal guanylate cyclase activity in children: effect of age and stimulation by Escherichia coli heat-stable enterotoxin," <i>Pediatr. Res.</i> (1987), 21(6), 551-555		
	CV	Grider J., "Interplay of VIP and nitric oxide in regulation of the descending relaxation phase of peristalsis," <i>Am. J. Physiol.</i> (1993) Feb;264(2 Pt 1):G334-40		
	CW	Hamra, F. K. et al., "Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase" <i>Proc. Natl. Acad. Sci. USA</i> (1993), 90(22), 10464-10468.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO				Complete if Known	
		<i>Application Number</i>	10/775481		
		<i>Filing Date</i>	February 10, 2004		
		<i>First Named Inventor</i>	Scott Waldman		
		<i>Art Unit</i>	1842		
		<i>Examiner Name</i>	Catherine Joyce		
Sheet	7	of	11	<i>Attorney Docket Number</i>	TJU0016-100 (WAL_SCO.008/CGG)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	CX	Harlow E. and D. Lane, ANTIBODIES: <i>A Laboratory Manual</i> , Cold Spring Harbor Laboratory, Cold spring Harbor NY (1988).		
	CY	Harrison, S. A et al., "Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs," <i>Mol. Pharmacol.</i> (1986 May);29(5):506-14.		
	CZ	Hill, O et al., "A new human guanylate cyclase-activating peptide (GCAP-II, uroguanylin): precursor cDNA and colonic expression," <i>Biocim BioPhys. Acta</i> (1995) 1253 (2), 146-149.		
	DA	Hill, D. R et al., "Health advice for international travel," <i>Ann. Intern. Med.</i> (1988), 108(6), 839-852.		
	DB	Hille, B., <i>Ionic Channels of Excitable Membranes</i> , (1984) 1 st edition (Sinauer Associates, Sunderland, MA) ISBN 0-87893-322-0.		
	DC	Hood, J. et al., "Protein kinase G mediates vascular endothelial growth factor-induced Raf-1 activation and proliferation in human endothelial cells," <i>J. Biol. Chem.</i> (1998), 273(36), 23504-23508.		
	DD	Hughes, J. M. et al., "Role of cyclic GMP in the action of heat-stable enterotoxin of Escherichia coli," <i>Nature</i> (1978), 271, 755-756.		
	DE	Kent and Clark-Lewis, <i>Synthetic Peptides in Biology and Medicine</i> , p.295-358 (Alitalo, K et al. Elsevier Science Publishers, Amsterdam, 1985).		
	DF	Knoop, F. C. et al., "Pharmacologic action of Escherichia coli heat-stable (STa) enterotoxin," <i>J. Pharmacol. Toxicol. Methods</i> (1992) 28(2), 67-72.		
	DG	Larrick and Fry, "Recombinant antibodies," <i>Hum. Antibod. and hybridomas</i> (1991), 2(4):172-89.		
	DH	Lucas, K. A. et al., "Guanylyl cyclases and signaling by cyclic GMP," <i>Pharmacol. Rev.</i> (2000), 52(3), 375-414.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<i>Application Number</i>	10/775481
(Use as many sheets as necessary)		<i>Filing Date</i>	February 10, 2004
		<i>First Named Inventor</i>	Scott Waldman
		<i>Art Unit</i>	1642
		<i>Examiner Name</i>	Catherine Joyce
Sheet	8	of	11
		<i>Attorney Docket Number</i>	TJU0016-100 (WAL_SCO.008/CGG)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	DI	McOmie J.F.W., <i>Protective Groups in Organic Chemistry</i> , Plenum Press, New York, NY (1973)		
	DJ	Merrifield, "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide," <i>J. Am. Chem. Soc.</i> (1963) 15:2149-2154.		
	DK	Miyazato, M. et al., "Uroguanylin gene expression in the alimentary tract and extra-gastrointestinal tissues," <i>FEBS Lett.</i> (1996), 398 (2-3), 170-174.		
	DL	Miyazato, M. et al., "Cloning and characterization of a cDNA encoding a precursor for human uroguanylin," <i>Biochem. Biophys Res. Commun.</i> (1996), 219 (2), 644-648.		
	DM	Miyazato, M. et al., "Genomic structure and chromosomal localization of human uroguanylin," <i>Genomics</i> (1997)43 (3), 359-365.		
	DN	Moseley et al., "Isolation and nucleotide sequence determination of a gene encoding a heat-stable enterotoxin of Escherichia coli," <i>Infect Immun.</i> (1983) 39(3):1167-74.		
	DO	Notterman, D. A. et al., "Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays," <i>Cancer Res.</i> (2001), 61(7), 3124-3130.		
	DP	Neurath, H et al., <i>The Proteins</i> , VOL II, 3d Ed., p.105-137., Academic Press, New York , NY (1976)		
	DQ	Okamoto, K. et al., "Substitutions of cysteine residues of Escherichia coli heat-stable enterotoxin by oligonucleotide-directed mutagenesis," <i>Infec. Immun.</i> (1985), 55:2121-2125.		
	DR	Parkinson, S. J. et al., "Interruption of Escherichia coli heat-stable enterotoxin-induced guanylyl cyclase signaling and associated chloride current in human intestinal cells by 2-chloroadenosine," <i>J. Biol. Chem.</i> (1997), 272(2), 754-758.		
	DS	Penman, I. D. et al., "Dietary calcium supplementation increases apoptosis in the distal murine colonic epithelium," <i>J. Clin. Pathol.</i> (2000), 53(4), 302-307.		

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 9 of 11

Complete if Known

Application Number	10/775481
Filing Date	February 10, 2004
First Named Inventor	Scott Waldman
Art Unit	1642
Examiner Name	Catherine Joyce
Attorney Docket Number	TJU0016-100 (WAL_SCO.008/CGG)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	DT	Pitari, G. M. et al., "Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells," <i>Proc. Natl. Acad. Sci. USA</i> (2001), 98(14), 7846-7851.	
	DU	Qiu, W. et al., "Cyclic nucleotide-gated cation channels mediate sodium and calcium influx in rat colon," <i>Am. J. Physiol.</i> (2000) 278(2), C336-C343.	
	DV	Rosado, J. A., "Cyclic nucleotides modulate store-mediated calcium entry through the activation of protein-tyrosine phosphatases and altered actin polymerization in human platelets," <i>J. Biol. Chem.</i> (2001) 276(19), 15666-15675.	
	DW	Sambrook et al., <i>Molecular Cloning: a Laboratory Manual</i> , Second Ed., Cold Spring Harbor Press (1989)	
	DX	Sauvage F.J. et al., "Primary structure and functional expression of the human receptor for Escherichia coli heat-stable enterotoxin," <i>Journal of Biol. Chemistry</i> (1991) 266(27):17912-8.	
	DY	Sesink, A. L. et al., "Red meat and colon cancer: dietary haem-induced colonic cytotoxicity and epithelial hyperproliferation are inhibited by calcium," <i>Carcinogenesis</i> (2001) 22(10), 1653-1659.	
	DZ	Schulz, S. et al., "Guanylyl cyclase is a heat-stable enterotoxin receptor," <i>Cell</i> (1990), 63(5), 941-948.	
	EA	Shailubhai, K. et al., "Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP," <i>Cancer Res.</i> (2000) 60(18), 5151-5157.	
	EB	Shimonishi, Y. et al., "Mode of disulfide bond formation of a heat-stable enterotoxin (STh) produced by a human strain of enterotoxigenic Escherichia coli," <i>FEBS Lett.</i> (1987), 215(1):165-170.	
	EC	So and McCarthy et al. "Nucleotide sequence of the bacterial transposon Tn1681 encoding a heat-stable (ST) toxin and its identification in enterotoxigenic Escherichia coli strains," <i>Proc. Natl. Acad. Sci USA</i> (1980), 77:4011-4015.	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			<i>Application Number</i>	10/775481
(Use as many sheets as necessary)			<i>Filing Date</i>	February 10, 2004
			<i>First Named Inventor</i>	Scott Waldman
			<i>Art Unit</i>	1642
			<i>Examiner Name</i>	Catherine Joyce
Sheet	10	of	11	Attorney Docket Number
TJU0016-100 (WAL_SCO.008/CGG)				

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	ED	Stern, J. H. et al., "Control of the light-regulated current in rod photoreceptors by cyclic GMP, calcium, and l-cis-diltiazem," <i>Proc. Natl. Acad. Sci. USA</i> (1986) 83(4), 1163-1167.		
	EE	Stuart J. and J.D. Young, <i>Solid Phase Peptide Synthelia</i> , Pierce Chemical Company, Rockford, IL (1984)		
	EF	Sugimoto, T. et al., "Atrial natriuretic peptide induces the expression of MKP-1, a mitogen-activated protein kinase phosphatase, in glomerular mesangial cells," <i>J. Biol. Chem.</i> (1996), 271(1), 544-547.		
	EG	Thompson, W. J. et al., "Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin," <i>Cancer Res.</i> (2000), 60(13), 3338-3342.		
	EH	Waldman, S.A. et al., "Influence of a glycine or proline substitution on the functional properties of a 14-amino-acid analog of Escherichia coli heat-stable enterotoxin," <i>Infect. Immun.</i> (1989) 57(8):2420-4.		
	EI	Vaandrager et al., "Guanosine 3',5'-cyclic monophosphate-dependent protein kinase II mediates heat-stable enterotoxin-provoked chloride secretion in rat intestine," <i>Gastroenterology</i> (1997) 112(2), 437-443.		
	EJ	Vaandrager et al., "Guanylyl cyclase C is an N-linked glycoprotein receptor that accounts for multiple heat-stable enterotoxin-binding proteins in the intestine," <i>J. Biolog. Chem.</i> (1993) 268(3):2174-2179.		
	EK	Vaandrager et al., "Differential role of cyclic GMP-dependent protein kinase II in ion transport in murine small intestine and colon," <i>Gastroenterology</i> (2000), 118(1), 108-114.		
	EL	Waldman, S. A. et al., "Heterogeneity of guanylyl cyclase C expressed by human colorectal cancer cell lines in vitro," <i>Cancer Epidemiol. Biomarkers Prev.</i> (1998) 7(6), 505-514.		
	EM	Wilmink, A. B. et al., "Overview of the epidemiology of colorectal cancer," <i>Dis. Colon Rectum</i> (1997) 40(4), 483-493		
	EN	Winter et al., "Man-made antibodies," <i>Nature</i> (1990), 349(6307):293-299.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO			<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			<i>Application Number</i>	10/775481
<i>(Use as many sheets as necessary)</i>			<i>Filing Date</i>	February 10, 2004
			<i>First Named Inventor</i>	Scott Waldman
			<i>Art Unit</i>	1642
			<i>Examiner Name</i>	Catherine Joyce
Sheet	11	of	11	Attorney Docket Number
TJU0016-100 (WAL_SCO.008/CGG)				

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	EO	Yoshimura, S. et al., "Essential structure for full enterotoxigenic activity of heat-stable enterotoxin produced by enterotoxigenic Escherichia coli" <i>FEBS Lett.</i> (1985) 181(1):138-142		
	EP	Zufall, F. et al., "Cyclic nucleotide gated channels as regulators of CNS development and plasticity," <i>Curr. Opin. Neurobiol.</i> (1997), 7(3), 404-412.		
	EQ	Zhang, W. et al., "Interruption of transmembrane signaling as a novel antisecretory strategy to treat enterotoxigenic diarrhea," <i>FASEB J.</i> (1999),13, 913-922		
	ER	Zingman, L. V. et al., "Signaling in channel/enzyme multimers: ATPase transitions in SUR module gate ATP-sensitive K ⁺ conductance," <i>Neuron</i> (2001) 31, 233-245.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.